Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 14/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003108 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2FFAR4EGFRLCKJAK3 | |
| SCHEMBL4153662 | 0.99 | SMN1; SMN2 (0.42) | SMN1; SMN2FFAR4EGFRLCKJAK3 | |
| SCHEMBL4004158 | 0.99 | SMN1; SMN2 (0.42) | SMN1; SMN2FFAR4EGFRLCKJAK3 | |
| SCHEMBL4002391 | 0.92 | SRD5A2 (0.43) | SMN1; SMN2FFAR4ACACBSRD5A2 | |
| SCHEMBL4147516 | 0.91 | EPHX1 (0.46) | SMN1; SMN2FFAR4EGFRLCKJAK3 | |
| SCHEMBL5950696 | 0.91 | ALDH1A1 (0.40) | SMN1; SMN2BTKACACBSRD5A2 | |
| SCHEMBL4009711 | 0.91 | SRD5A2 (0.40) | SMN1; SMN2FFAR4EGFRLCKJAK3 | |
| SCHEMBL5950727 | 0.88 | GPR119 (0.42) | LCKJAK3SRD5A2 | |
| SCHEMBL5950205 | 0.86 | ACACB (0.39) | ACACB | |
| SCHEMBL4149415 | 0.86 | EPHX1 (0.43) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | claimed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SMN1; SMN2 3627/4885FFAR4 1444/4885EGFR 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.